Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds

Shadow Of The Opioid Crisis Looms Large Over Israeli Generics Firm

Executive Summary

Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.

You may also be interested in...



Teva Wins Support For Nationwide Opioid Settlement With Bigger Cash Offer

Teva to pay $4.25bn over 13 years under agreement in principle with 12 state attorneys general, Native American tribes and plaintiffs’ lawyers. Previous settlement offer provided mostly medication. Deal is contingent on governments signing on and Allergan inking settlement.

Teva Finds Relief In US Opioid Crisis Settlement, Updates Long-Term Objectives

The Israeli firm announced a US-wide settlement for opioid crisis litigation that has been hanging over it for years, as forex took its toll on its second-quarter revenues.

Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement

Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel